Robert Scott, MD
Family Practice · Port Angeles, WANPI 1891887857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 45.9% of the total. Reporting peaked in 2019 at $511 and has fallen 80.6% since, to $99 in 2024. Among family practice clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$462
- AstraZeneca$112
- Mimedx Group, Inc.$99
- Novo Nordisk$90
- Boehringer Ingelheim$52
- Abbott$49
- plus $143 from 4 others
What the payments were for
- Food & beverage$99899%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $462 |
| AstraZeneca | 7 | $112 |
| Mimedx Group, Inc. | 1 | $99 |
| Novo Nordisk | 5 | $90 |
| Boehringer Ingelheim | 4 | $52 |
| Abbott | 2 | $49 |
| Novartis | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Pfizer | 2 | $34 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$119
How this compares
$1,007 in reported general payments places this provider in the 95th percentile of 1,295 family practice providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 26 | $49,950 |
| EliquisApixaban | 28 | $29,029 |
| XareltoRivaroxaban | 27 | $24,803 |
| JardianceEmpagliflozin | 16 | $21,205 |
| OzempicSemaglutide | 11 | $19,442 |
| FarxigaDapagliflozin Propanediol | 12 | $16,645 |
| Atorvastatin Calcium | 139 | $1,542 |
| Rosuvastatin Calcium | 56 | $1,472 |
| Metoprolol Succinate | 79 | $1,444 |
| Levothyroxine Sodium | 56 | $726 |
| Amlodipine Besylate | 91 | $711 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $691 |
| Trazodone Hcl | 21 | $596 |
| Losartan Potassium | 39 | $585 |
| Lisinopril | 78 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $462 | $49,95026 claims |
| PfizerEliquis | $34 | $29,02928 claims |
| Boehringer IngelheimJardiance | $52 | $21,20516 claims |
| Novo NordiskOzempic | $90 | $19,44211 claims |
| AstraZenecaFarxiga | $112 | $16,64512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,295 family practice providers in Washington.
Other family practice in Port Angeles
- Matthew SturmPort Angeles$0
- Brandi BodenBonney Lake$104
- Aaron BrinklowArlington$79
- Darcy RobbinsSpokane$68
- Caryn LawrenceVancouver$61
- Collena ButlerTacoma$22
- Mark LarsonEllensburg$21
- Daniel CoppSeattle$0
- Darien JourdaineEverett$0
- Natasha WuBellevue$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.